Gilead Sciences to invest $300m in VC-backed Tizona Therapeutics

Gilead Sciences Inc has agreed to invest $300 million in Tizona Therapeutics, a clinical-stage immunotherapy company.

To read this article, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to read this article and more for free.

Share this